JP2016506928A - アルコキシル化天然ワックスを有する眼用組成物 - Google Patents
アルコキシル化天然ワックスを有する眼用組成物 Download PDFInfo
- Publication number
- JP2016506928A JP2016506928A JP2015555260A JP2015555260A JP2016506928A JP 2016506928 A JP2016506928 A JP 2016506928A JP 2015555260 A JP2015555260 A JP 2015555260A JP 2015555260 A JP2015555260 A JP 2015555260A JP 2016506928 A JP2016506928 A JP 2016506928A
- Authority
- JP
- Japan
- Prior art keywords
- poly
- lanolin
- jojoba
- ppm
- amine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 79
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 82
- 239000004166 Lanolin Substances 0.000 claims abstract description 68
- 229940039717 lanolin Drugs 0.000 claims abstract description 67
- 239000001993 wax Substances 0.000 claims abstract description 64
- 235000019388 lanolin Nutrition 0.000 claims abstract description 57
- 241000221095 Simmondsia Species 0.000 claims abstract description 44
- 235000004433 Simmondsia californica Nutrition 0.000 claims abstract description 44
- 150000001412 amines Chemical class 0.000 claims abstract description 43
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 41
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims abstract description 20
- 206010013774 Dry eye Diseases 0.000 claims abstract description 20
- 238000000034 method Methods 0.000 claims abstract description 16
- 235000013871 bee wax Nutrition 0.000 claims abstract description 10
- 239000012166 beeswax Substances 0.000 claims abstract description 10
- -1 hydroxypropyl Chemical group 0.000 claims description 28
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 21
- 229920002674 hyaluronan Polymers 0.000 claims description 21
- 229960003160 hyaluronic acid Drugs 0.000 claims description 21
- 229920002873 Polyethylenimine Polymers 0.000 claims description 20
- 230000000845 anti-microbial effect Effects 0.000 claims description 12
- LFVVNPBBFUSSHL-UHFFFAOYSA-N alexidine Chemical compound CCCCC(CC)CNC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NCC(CC)CCCC LFVVNPBBFUSSHL-UHFFFAOYSA-N 0.000 claims description 8
- 229950010221 alexidine Drugs 0.000 claims description 8
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims description 7
- VAZJLPXFVQHDFB-UHFFFAOYSA-N 1-(diaminomethylidene)-2-hexylguanidine Polymers CCCCCCN=C(N)N=C(N)N VAZJLPXFVQHDFB-UHFFFAOYSA-N 0.000 claims description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 239000007983 Tris buffer Substances 0.000 claims description 6
- 239000003889 eye drop Substances 0.000 claims description 6
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims description 5
- 239000000017 hydrogel Substances 0.000 claims description 5
- 239000006196 drop Substances 0.000 claims description 4
- 229920001296 polysiloxane Polymers 0.000 claims description 4
- GAGSAAHZRBTRGD-UHFFFAOYSA-N oxirane;oxolane Chemical compound C1CO1.C1CCOC1 GAGSAAHZRBTRGD-UHFFFAOYSA-N 0.000 claims description 3
- UURVHRGPGCBHIC-UHFFFAOYSA-N 3-(ethenoxycarbonylamino)propanoic acid 4-[[[[[[[[[[[[[[[[[[[[[[[[[[[4-ethenoxycarbonyloxybutyl(dimethyl)silyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]butyl ethenyl carbonate 1-ethenylpyrrolidin-2-one ethenyl N-[3-tris(trimethylsilyloxy)silylpropyl]carbamate Chemical compound C=CN1CCCC1=O.OC(=O)CCNC(=O)OC=C.C[Si](C)(C)O[Si](CCCNC(=O)OC=C)(O[Si](C)(C)C)O[Si](C)(C)C.C[Si](C)(CCCCOC(=O)OC=C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)CCCCOC(=O)OC=C UURVHRGPGCBHIC-UHFFFAOYSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- 235000010447 xylitol Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 2
- 239000004202 carbamide Substances 0.000 claims 2
- UXFQFBNBSPQBJW-UHFFFAOYSA-N 2-amino-2-methylpropane-1,3-diol Chemical compound OCC(N)(C)CO UXFQFBNBSPQBJW-UHFFFAOYSA-N 0.000 claims 1
- 244000007835 Cyamopsis tetragonoloba Species 0.000 claims 1
- 235000019270 ammonium chloride Nutrition 0.000 claims 1
- 238000007598 dipping method Methods 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 239000000243 solution Substances 0.000 description 71
- 229920001223 polyethylene glycol Polymers 0.000 description 28
- 239000004094 surface-active agent Substances 0.000 description 15
- 239000000872 buffer Substances 0.000 description 12
- 244000303965 Cyamopsis psoralioides Species 0.000 description 11
- 125000002091 cationic group Chemical group 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 11
- 229920000642 polymer Polymers 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 9
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 9
- 229910019142 PO4 Inorganic materials 0.000 description 8
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 150000002632 lipids Chemical class 0.000 description 8
- 239000010452 phosphate Substances 0.000 description 8
- 235000021317 phosphate Nutrition 0.000 description 8
- 229920001983 poloxamer Polymers 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 8
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 7
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 7
- 239000004327 boric acid Substances 0.000 description 7
- 238000004140 cleaning Methods 0.000 description 7
- 229920000570 polyether Polymers 0.000 description 7
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- 229920002413 Polyhexanide Polymers 0.000 description 6
- 230000000844 anti-bacterial effect Effects 0.000 description 6
- 229920001400 block copolymer Polymers 0.000 description 6
- 229920001577 copolymer Polymers 0.000 description 6
- 229940119170 jojoba wax Drugs 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 125000000217 alkyl group Chemical group 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000002736 nonionic surfactant Substances 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 238000004806 packaging method and process Methods 0.000 description 5
- 239000008363 phosphate buffer Substances 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 229940123208 Biguanide Drugs 0.000 description 4
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 4
- 229920003171 Poly (ethylene oxide) Chemical group 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 4
- 230000003139 buffering effect Effects 0.000 description 4
- 239000002738 chelating agent Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000000249 desinfective effect Effects 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 229940012356 eye drops Drugs 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 229960000502 poloxamer Drugs 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 150000005846 sugar alcohols Chemical class 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 3
- 235000004866 D-panthenol Nutrition 0.000 description 3
- 239000011703 D-panthenol Substances 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 229920002907 Guar gum Polymers 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 239000004721 Polyphenylene oxide Substances 0.000 description 3
- 229920002385 Sodium hyaluronate Polymers 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229910021538 borax Inorganic materials 0.000 description 3
- 239000006172 buffering agent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 239000000665 guar gum Substances 0.000 description 3
- 229960002154 guar gum Drugs 0.000 description 3
- 235000010417 guar gum Nutrition 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 125000005702 oxyalkylene group Chemical group 0.000 description 3
- 229920001987 poloxamine Polymers 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 229940010747 sodium hyaluronate Drugs 0.000 description 3
- 235000010339 sodium tetraborate Nutrition 0.000 description 3
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000008719 thickening Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- 0 CCC*C(CC1)(C2)CCC3(C)*12C3C(C)C(C)(CC)CC(C)C(C)CCCC(C)C(C)C Chemical compound CCC*C(CC1)(C2)CCC3(C)*12C3C(C)C(C)(CC)CC(C)C(C)CCCC(C)C(C)C 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 229920002511 Poloxamer 237 Polymers 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 2
- 229920002359 Tetronic® Polymers 0.000 description 2
- 239000004164 Wax ester Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000000607 artificial tear Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000001311 chemical methods and process Methods 0.000 description 2
- 239000000882 contact lens solution Substances 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000007046 ethoxylation reaction Methods 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 208000030533 eye disease Diseases 0.000 description 2
- 210000000744 eyelid Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000002997 ophthalmic solution Substances 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 229920001992 poloxamer 407 Polymers 0.000 description 2
- 229940044476 poloxamer 407 Drugs 0.000 description 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 2
- 239000004926 polymethyl methacrylate Substances 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 210000002374 sebum Anatomy 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- 235000019386 wax ester Nutrition 0.000 description 2
- 210000002268 wool Anatomy 0.000 description 2
- CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 description 1
- OYINQIKIQCNQOX-UHFFFAOYSA-M 2-hydroxybutyl(trimethyl)azanium;chloride Chemical group [Cl-].CCC(O)C[N+](C)(C)C OYINQIKIQCNQOX-UHFFFAOYSA-M 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 241000256837 Apidae Species 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical class C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- NHYCGSASNAIGLD-UHFFFAOYSA-N Chlorine monoxide Chemical class Cl[O] NHYCGSASNAIGLD-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 244000180278 Copernicia prunifera Species 0.000 description 1
- 235000010919 Copernicia prunifera Nutrition 0.000 description 1
- 235000008222 Cyamopsis psoralioides Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 206010015946 Eye irritation Diseases 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- 240000003444 Paullinia cupana Species 0.000 description 1
- 235000000556 Paullinia cupana Nutrition 0.000 description 1
- 229920001090 Polyaminopropyl biguanide Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 241001111950 Sonora Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- FZQSLXQPHPOTHG-UHFFFAOYSA-N [K+].[K+].O1B([O-])OB2OB([O-])OB1O2 Chemical compound [K+].[K+].O1B([O-])OB2OB([O-])OB1O2 FZQSLXQPHPOTHG-UHFFFAOYSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910000318 alkali metal phosphate Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 229910000316 alkaline earth metal phosphate Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 125000003550 alpha-D-galactosyl group Chemical group C1([C@H](O)[C@@H](O)[C@@H](O)[C@H](O1)CO)* 0.000 description 1
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000001384 anti-glaucoma Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000002199 base oil Substances 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- QBWCMBCROVPCKQ-UHFFFAOYSA-N chlorous acid Chemical class OCl=O QBWCMBCROVPCKQ-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 229960003949 dexpanthenol Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 125000000600 disaccharide group Chemical group 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- SYELZBGXAIXKHU-UHFFFAOYSA-N dodecyldimethylamine N-oxide Chemical compound CCCCCCCCCCCC[N+](C)(C)[O-] SYELZBGXAIXKHU-UHFFFAOYSA-N 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000000806 elastomer Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 229940071087 ethylenediamine disuccinate Drugs 0.000 description 1
- 231100000013 eye irritation Toxicity 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 201000010666 keratoconjunctivitis Diseases 0.000 description 1
- 210000004561 lacrimal apparatus Anatomy 0.000 description 1
- 229940048866 lauramine oxide Drugs 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 208000018769 loss of vision Diseases 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 229940023490 ophthalmic product Drugs 0.000 description 1
- 229940054534 ophthalmic solution Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 125000006353 oxyethylene group Chemical group 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229940044519 poloxamer 188 Drugs 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- JVUYWILPYBCNNG-UHFFFAOYSA-N potassium;oxido(oxo)borane Chemical compound [K+].[O-]B=O JVUYWILPYBCNNG-UHFFFAOYSA-N 0.000 description 1
- 239000003761 preservation solution Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 150000003335 secondary amines Chemical group 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 108010019783 tear proteins Proteins 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- WUUHFRRPHJEEKV-UHFFFAOYSA-N tripotassium borate Chemical compound [K+].[K+].[K+].[O-]B([O-])[O-] WUUHFRRPHJEEKV-UHFFFAOYSA-N 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229920001664 tyloxapol Polymers 0.000 description 1
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical group O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 description 1
- 229960004224 tyloxapol Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000010698 whale oil Substances 0.000 description 1
- 229940045860 white wax Drugs 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11C—FATTY ACIDS FROM FATS, OILS OR WAXES; CANDLES; FATS, OILS OR FATTY ACIDS BY CHEMICAL MODIFICATION OF FATS, OILS, OR FATTY ACIDS OBTAINED THEREFROM
- C11C3/00—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom
- C11C3/04—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom by esterification of fats or fatty oils
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
- A61K35/644—Beeswax; Propolis; Royal jelly; Honey
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L12/00—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor
- A61L12/08—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor using chemical substances
- A61L12/14—Organic compounds not covered by groups A61L12/10 or A61L12/12
- A61L12/141—Biguanides, e.g. chlorhexidine
- A61L12/142—Polymeric biguanides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
- C08G73/02—Polyamines
- C08G73/0206—Polyalkylene(poly)amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
Abstract
Description
式中、Rは、−H、−CH3、−C2H5、−OHおよび−CH2OHであり;mは2、3、4、5または6であり;nは、mが2または3である場合、8から110の整数であり、nは、mが4、5または6である場合、6から60の整数である。より好ましい天然ワックスのいくつかとして、蜜蝋、ラノリン、PEGラノリン、ホホバおよびPEGホホバが挙げられる。
式中、Rは、−H、−CH3、−C2H5、−OHおよび−CH2OHであり;mは2、3、4、5または6であり;nは、mが2または3である場合、8から110の整数であり、nは、mが4、5または6である場合、6から60の整数である。
R1は、Rまたは−(CH2)n−NHC(O)Rであり、Rは、ヒドロキシルにより必要に応じて置換されたC8〜C16アルキルであり、nは、2、3または4であり;R2およびR3は、メチル、エチル、プロピルまたはイソプロピルから各々独立して選択され;R4は、ヒドロキシルにより必要に応じて置換されたC2〜C8アルキレンである。あるいは、一般式B
R1は、少なくとも1つのヒドロキシルにより置換されたC8〜C16アルキルであり;R2およびR3は、メチル、エチル、プロピルまたはイソプロピルから各々独立して選択され;R4は、少なくとも1つのヒドロキシルにより置換されたC2〜C8アルキレンである。
R1は、水素、アルキルまたは−C(O)アルキルから選択され、そのアルキルは、1から12の炭素および必要に応じて1つ以上の酸素原子を有し、Aは、メチレン基またはオキシアルキレン基であり、nは2から8までである。1つの実施の形態において、ジコハク酸塩は、S,S−エチレンジアミンジコハク酸塩(S,S−EDDS)またはその対応する塩である。S,S−EDDSの商業的供給源の1つは、Octaquest(登録商標)E30により示され、これは、Octel社から市販されている。S,S−EDDSの三ナトリウム塩の化学構造が下記に示されている。その塩は、カルシウムやマグネシウムなどのアルカリ土類金属も含んで差し支えない。このジコハク酸塩の亜鉛塩または銀塩も前記眼用組成物に使用して差し支えない。
Mw=1,300の分子量を有する分岐鎖ポリ(エチレンイミン)(PEI、BASF−SE)の水溶液を調製する。一般に、分岐鎖PEIは、1:2:1の比で、第一級、第二級および第三級の基を含み、それらの分岐部位は、主に、第二級アミン基により隔てられている(直鎖内の3〜3.5N原子毎に1つの分岐)。
ポリ(エチレンイミン)−PEG−ラノリンの合成 PEG75−ラノリンのポリエーテル鎖の結合していないヒドロキシル基を、最初に、1,1’−カルボニルジイミダゾールとの反応により活性化させる。次いで、活性化されたPEG75−ラノリンをポリ(エチレンイミン)の結合していないアミノ基と結合させて、所望のPEI−PEG−ラノリンを形成する。
ポリ(エチレンイミン)−PEG−ホホバの合成 PEG150−ホホバのポリエーテル鎖の結合していないヒドロキシル基を、最初に、1,1’−カルボニルジイミダゾールとの反応により活性化させる。次いで、活性化されたPEG150−ホホバをポリ(エチレンイミン)の結合していないアミノ基と結合させて、所望のPEI−PEG−ホホバを形成する。
PEI−ラノリンの合成 天然ワックスラノリンの結合していない酸性基を、最初に、1,1’−カルボニルジイミダゾールとの反応により活性化させる。次いで、活性化されたラノリンをポリ(エチレンイミン)の結合していないアミノ基と結合させて、所望のPEI−ラノリンを形成する。
PEI−ホホバの合成 天然ワックスホホバの結合していない酸性基を、最初に、1,1’−カルボニルジイミダゾールとの反応により活性化させる。次いで、活性化されたホホバをポリ(エチレンイミン)の結合していないアミノ基と結合させて、所望のPEI−ホホバを形成する。
以下のプロセス(成分は、ppmで示されていない限り、質量%で列挙されている)を使用して、表5の実施例5から9のコンタクトレンズケア溶液を調製する。ステンレス鋼製混合容器に、全バッチ質量の70〜90%に等しい体積の精製水を加える。以下のバッチ配合量の成分を、列挙された順序で撹拌しながら水に加える:塩化ナトリウム、エデト酸二ナトリウム、ホウ酸、ホウ酸ナトリウム、ポリ(エチレンイミン)ラノリン。各成分を確実に完全に溶解させるために、その溶液は10分間以上に亘り混合(撹拌)する。ヒアルロン酸ナトリウムを加えるべき場合には、溶液は、70℃以上の温度まで温め、次いで、ヒアルロン酸ナトリウムを加える。暖められた溶液を、ヒアルロン酸ナトリウムが完全に溶解されたように見えるまで、少なくとも20分間に亘り撹拌する。得られた溶液のpHを室温で測定し、必要であれば、1NのNaOHまたは1NのHClでpHを調節する(標的pH=7.5)。第2のステンレス鋼製容器内で、バッチに必要な測定量のPHMBを所定の量の精製水に加え、その溶液を少なくとも10分間に亘り撹拌する。
PEI−ラノリンの代わりに、実施例4のPEI−ホホバを使用したことを除いて、実施例10から14を、実施例5から9に使用した方法と成分濃度にしたがって調製する。
PEI−ラノリンの代わりに、実施例1のPEI−PEG75−ラノリンを使用したことを除いて、実施例15から19を、実施例5から9に使用した方法と成分濃度にしたがって調製する。
PEI−ラノリンの代わりに、実施例2のPEI−PEG150−ホホバを使用したことを除いて、実施例20から24を、実施例5から9に使用した方法と成分濃度にしたがって調製する。
Claims (18)
- 前記天然ワックスが、蜜蝋、ラノリン、PEGラノリン、ホホバおよびPEGホホバからなる群より選択される、請求項1記載の組成物。
- 0.002質量%から0.2質量%のヒアルロン酸または0.05質量%から0.3質量%のヒドロキシプロピルグアーをさらに含む、請求項1または2記載の組成物。
- 前記天然ワックスのポリ(窒素/アミン)誘導体がポリエチレンイミンラノリンであり、該ポリエチレンイミンラノリンが0.005質量%から0.3質量%で存在する、請求項1から3いずれか1項記載の組成物。
- 前記ポリエチレンイミンラノリンが、600ダルトンから6000ダルトンまでの数平均分子量を有する、請求項4記載の組成物。
- 前記天然ワックスのポリ(窒素/アミン)誘導体がポリエチレンイミンホホバであり、該ポリエチレンイミンホホバが0.005質量%から1.0質量%で存在する、請求項1から3いずれか1項記載の組成物。
- 前記ポリエチレンイミンホホバが、600ダルトンから6000ダルトンまでの数平均分子量を有する、請求項6記載の組成物。
- 医薬品をさらに含む、請求項1から7いずれか1項記載の組成物。
- デクスパンテノール、ソルビトール、キシリトール、グリコール酸、プロピレングリコール、2−アミノ−2−メチル−1,3−プロパンジオール、ポリ(エチレンオキシド−ブチレンオキシド)またはそれらの任意の混合物をさらに含む、請求項1から8いずれか1項記載の組成物。
- 0.5ppmから1.5ppmの量で存在する、ポリ(ヘキサメチレンビグアニド);1ppmから10ppmの量で存在する、α−[4−トリス(2−ヒドロキシエチル)−アンモニウムクロライド−2−ブテニル]ポリ[1−ジメチルアンモニウムクロライド−2−ブテニル]−ω−トリス(2−ヒドロキシエチル)アンモニウムクロライド;および1ppmから4ppmの量で存在する、アレキシジンからなる群より選択される1種類以上の抗菌性成分をさらに含む、請求項1から9いずれか1項記載の組成物。
- 0.5ppmから1.5ppmのポリ(ヘキサメチレンビグアニド)、または1ppmから4ppmのアレキシジンをさらに含み、
式(I)の天然ワックスの前記ポリ(窒素/アミン)誘導体が、該誘導体化天然ワックスを含まない対応する組成物に対して、前記組成物および前記対応する組成物中にバラフィルコンAのシリコーンハイドロゲルコンタクトレンズを6時間に亘り浸漬した後、バラフィルコンAのレンズ中に吸収される前記ポリ(ヘキサメチレンビグアニド)またはアレキシジンの量を少なくとも25%減少させる、請求項1から9いずれか1項記載の組成物。 - 1ppmから3ppmの量で存在する、α−[4−トリス(2−ヒドロキシエチル)−アンモニウムクロライド−2−ブテニル]ポリ[1−ジメチルアンモニウムクロライド−2−ブテニル]−ω−トリス(2−ヒドロキシエチル)アンモニウムクロライドをさらに含む、請求項11記載の組成物。
- 前記天然ワックスが、蜜蝋、ラノリン、PEGラノリン、ホホバおよびPEGホホバからなる群より選択される、請求項13記載の方法。
- 前記患者がコンタクトレンズを装着し、前記点眼薬の1滴以上が、該患者の眼内に置かれたレンズに直接投与される、請求項13または14記載の方法。
- 600ダルトンから6000ダルトンまでの数平均分子量を有する、請求項16記載のポリ(尿素/アミン)誘導体。
- 前記天然ワックスが、蜜蝋、ラノリン、PEGラノリン、ホホバおよびPEGホホバからなる群より選択される、請求項16または17記載のポリ(尿素/アミン)誘導体。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361756206P | 2013-01-24 | 2013-01-24 | |
US61/756,206 | 2013-01-24 | ||
PCT/US2014/012676 WO2014116787A1 (en) | 2013-01-24 | 2014-01-23 | Poly(nitrogen/amine) derivatives of a natural wax and ophthalmic compositions |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2016506928A true JP2016506928A (ja) | 2016-03-07 |
JP2016506928A5 JP2016506928A5 (ja) | 2017-02-23 |
JP6290929B2 JP6290929B2 (ja) | 2018-03-07 |
Family
ID=50069330
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015555260A Active JP6290929B2 (ja) | 2013-01-24 | 2014-01-23 | アルコキシル化天然ワックスを有する眼用組成物 |
Country Status (10)
Country | Link |
---|---|
US (1) | US9279095B2 (ja) |
EP (1) | EP2948196B1 (ja) |
JP (1) | JP6290929B2 (ja) |
KR (1) | KR102225415B1 (ja) |
CN (1) | CN105188779B (ja) |
AU (1) | AU2014209426B2 (ja) |
CA (1) | CA2898483C (ja) |
ES (1) | ES2641169T3 (ja) |
PL (1) | PL2948196T3 (ja) |
WO (1) | WO2014116787A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016535290A (ja) * | 2013-09-27 | 2016-11-10 | ノバルティス アーゲー | コンタクトレンズを消毒及び洗浄するための組成物及び方法 |
JP2019163210A (ja) * | 2018-03-19 | 2019-09-26 | ライオン株式会社 | 水性眼科用組成物 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2936239A1 (en) * | 2014-01-16 | 2015-07-23 | Ontogenesis, Llc | Compositions and methods for the treatment of intraocular neovascularization and/or leakage |
GB201621050D0 (en) * | 2016-12-12 | 2017-01-25 | Provita Eurotech Ltd | Antimicrobial compositions |
CN113423387A (zh) | 2018-12-10 | 2021-09-21 | 埃特娜蒂尔公司 | 提供持久眼部润滑的眼用制剂 |
US11679078B1 (en) | 2022-03-08 | 2023-06-20 | EternaTear, Inc. | Ophthalmic formulations and related methods |
US11471475B1 (en) | 2022-03-08 | 2022-10-18 | Ralph P. Stone | Ophthalmic suspension vehicles and related methods for pharmaceutical ingredient delivery |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000516300A (ja) * | 1997-07-29 | 2000-12-05 | アルコン ラボラトリーズ,インコーポレイテッド | ハードコンタクトレンズ・ケアのためのコンディショニング溶液 |
JP2007528897A (ja) * | 2004-03-12 | 2007-10-18 | メルビ ホールディングス, エルエルシー | 眼表面用の潤滑剤 |
JP2008273959A (ja) * | 2007-04-04 | 2008-11-13 | Taisho Pharmaceutical Co Ltd | 点眼剤 |
WO2010077743A1 (en) * | 2008-12-09 | 2010-07-08 | L'oreal S.A. | Water-insoluble reaction product of a polyamine and an oil-soluble polar modified polymer |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4409205A (en) | 1979-03-05 | 1983-10-11 | Cooper Laboratories, Inc. | Ophthalmic solution |
US4758595A (en) | 1984-12-11 | 1988-07-19 | Bausch & Lomb Incorporated | Disinfecting and preserving systems and methods of use |
US5209927A (en) | 1985-01-23 | 1993-05-11 | Alcon Laboratories, Inc. | Ophthalmic solution |
ATE132366T1 (de) | 1990-05-29 | 1996-01-15 | Boston Ocular Res | Zusammensetzung zur behandlung von dry eye erkrankungen |
US5300287A (en) | 1992-11-04 | 1994-04-05 | Alcon Laboratories, Inc. | Polymeric antimicrobials and their use in pharmaceutical compositions |
JPH09507513A (ja) | 1993-12-29 | 1997-07-29 | ボシュ アンド ロム インコーポレイテッド | コンタクトレンズを洗浄および消毒するための炭水化物組成物および方法 |
TWI322828B (en) | 2002-12-23 | 2010-04-01 | Alcon Inc | Use of multifunctional surface active agents to clean contact lenses |
US8455016B2 (en) * | 2004-03-12 | 2013-06-04 | Melbj Holdings, Llc | Treatment for meibomian gland dysfunction or obstruction |
US20050202097A1 (en) * | 2004-03-12 | 2005-09-15 | Melbj Holdings, Llc, Florida | Lubricant for the ocular surface |
EP2398499B1 (en) * | 2009-02-18 | 2017-09-06 | Eyeon Particle Sciences LLC | Bi-functional co-polymer use for ophthalmic and other topical and local applications |
US20100086514A1 (en) | 2009-10-01 | 2010-04-08 | Liu X Michael | Contact Lens Care Solutions with a Low Molecular Weight Oligomer |
-
2014
- 2014-01-23 EP EP14703231.2A patent/EP2948196B1/en active Active
- 2014-01-23 US US14/161,936 patent/US9279095B2/en active Active
- 2014-01-23 JP JP2015555260A patent/JP6290929B2/ja active Active
- 2014-01-23 CN CN201480016501.7A patent/CN105188779B/zh active Active
- 2014-01-23 ES ES14703231.2T patent/ES2641169T3/es active Active
- 2014-01-23 WO PCT/US2014/012676 patent/WO2014116787A1/en active Application Filing
- 2014-01-23 AU AU2014209426A patent/AU2014209426B2/en active Active
- 2014-01-23 CA CA2898483A patent/CA2898483C/en active Active
- 2014-01-23 KR KR1020157022398A patent/KR102225415B1/ko active IP Right Grant
- 2014-01-23 PL PL14703231T patent/PL2948196T3/pl unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000516300A (ja) * | 1997-07-29 | 2000-12-05 | アルコン ラボラトリーズ,インコーポレイテッド | ハードコンタクトレンズ・ケアのためのコンディショニング溶液 |
JP2007528897A (ja) * | 2004-03-12 | 2007-10-18 | メルビ ホールディングス, エルエルシー | 眼表面用の潤滑剤 |
JP2008273959A (ja) * | 2007-04-04 | 2008-11-13 | Taisho Pharmaceutical Co Ltd | 点眼剤 |
WO2010077743A1 (en) * | 2008-12-09 | 2010-07-08 | L'oreal S.A. | Water-insoluble reaction product of a polyamine and an oil-soluble polar modified polymer |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016535290A (ja) * | 2013-09-27 | 2016-11-10 | ノバルティス アーゲー | コンタクトレンズを消毒及び洗浄するための組成物及び方法 |
JP2019163210A (ja) * | 2018-03-19 | 2019-09-26 | ライオン株式会社 | 水性眼科用組成物 |
Also Published As
Publication number | Publication date |
---|---|
KR102225415B1 (ko) | 2021-03-08 |
KR20150110662A (ko) | 2015-10-02 |
CA2898483C (en) | 2020-09-01 |
JP6290929B2 (ja) | 2018-03-07 |
WO2014116787A1 (en) | 2014-07-31 |
US9279095B2 (en) | 2016-03-08 |
AU2014209426A1 (en) | 2015-07-30 |
CN105188779B (zh) | 2017-12-12 |
CA2898483A1 (en) | 2014-07-31 |
PL2948196T3 (pl) | 2018-01-31 |
EP2948196A1 (en) | 2015-12-02 |
AU2014209426B2 (en) | 2016-12-22 |
CN105188779A (zh) | 2015-12-23 |
EP2948196B1 (en) | 2017-08-23 |
US20140206764A1 (en) | 2014-07-24 |
ES2641169T3 (es) | 2017-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6290929B2 (ja) | アルコキシル化天然ワックスを有する眼用組成物 | |
ES2374607T3 (es) | Composiciones oftálmicas con un tensioactivo anfótero y ácido hialurónico. | |
JP5543346B2 (ja) | カルボキシル修飾されたフルクタンまたはその塩を含む眼科用組成物 | |
US20100178317A1 (en) | Lens Care Solutions with Hyaluronic Acid | |
KR101726029B1 (ko) | 알콕실화된 천연 왁스를 갖는 안과용 조성물 | |
EP2903655B1 (en) | Minimizing biological lipid deposits on contact lenses | |
WO2020140365A1 (zh) | 一种含有黄原胶的保湿润滑组合物及其应用 | |
US8889160B2 (en) | Ophthalmic compositions with biguanide and PEG-glycerol esters | |
WO2007073480A1 (en) | A method for cleaning and maintaining contact lenses and related system and kit |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170119 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170119 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170905 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171129 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180109 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180208 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6290929 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |